公司資料
Nektar Therapeutics 股價、新聞與催化劑
- 股票代碼:
- NKTR
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
72.67 USD (-0.48%)
收盤價
最後更新: 2026年8月17日
1.98B USD
市值
股價為何變動
As of Aug 17, 2026, NKTR closed down 0.48% at $72.67. No new same-company headline was identified in the current news window.
公司概覽
Immune-Regulatory Therapeutics
Nektar Therapeutics develops biologic medicines that selectively modulate immune-cell pathways. Its current portfolio emphasizes regulatory T-cell biology for autoimmune and inflammatory diseases.
Rezpegaldesleukin
Rezpegaldesleukin is an IL-2 pathway agonist designed to expand and activate regulatory T cells without broadly stimulating conventional effector T cells.
Atopic-Dermatitis Development
The Phase 3 ZENITH-AD program is designed to test rezpegaldesleukin in moderate-to-severe atopic dermatitis after Phase 2b results showed responses during treatment and follow-up.
Alopecia-Areata Development
The REZOLVE-AA program evaluates rezpegaldesleukin in severe alopecia areata, including whether treatment effects persist during an off-treatment observation period.
Type 1 Diabetes and Earlier Pipeline
Rezpegaldesleukin is also being studied in a TrialNet-sponsored Phase 2 type 1 diabetes trial. Nektar's earlier portfolio includes TNFR2-directed antibodies such as NKTR-0165.
未來催化劑
- Initiation of a registrational Phase 3 study of rezpegaldesleukin in alopecia areata in early 2027.
- Initial Phase 3 ZENITH-AD data for rezpegaldesleukin in atopic dermatitis in mid-2028.
- First planned BLA submission for rezpegaldesleukin in 2029.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。